TRIAL OF LOVASTATIN AND ASPIRIN IN ATHEROSCLEROSIS

这项合作双盲安慰剂的主要目标是 对照试验是使用因子设计来确定是否 阿司匹林（324 毫克/天）或洛伐他汀（20-40 毫克/天），平均水平 治疗期三年，延缓病情进展 高危颈动脉中的动脉粥样硬化斑块 无症状颈动脉狭窄的个体。 男人和女人 无临床明显的冠心病和脑血管疾病 50 岁或以上，血清总胆固醇水平 浓度大约介于第 50 级 (220 mg/dl) 和 90 级 (260 mg/dl) 之间 mg/dl) 百分位数和至少一个具有一定厚度的斑块 1.0 至 4.0 毫米之间有资格参与。 一个 次要目标是确定长期的安全性 单独或联合进行两种主动干预治疗 组合。 冠心病和脑血管事件将 进行监测和自然历史研究。 将确定动脉粥样硬化病变的进展 每半年一次。 距离远端壁的平均壁厚 颈动脉（总动脉、分叉动脉和内动脉）将是 主要结果指标。 最大壁厚/最小壁厚 流明直径以及全局范围也将被确定 得分。 降脂治疗的目标是使总血脂 血清胆固醇低于 180 mg/dl。 试验的良好结果将对公共卫生产生重大影响 对预防/控制动脉粥样硬化及其疾病的影响 并发症。 B型成像的成功应用 将极大地影响医疗保健（监测牙菌斑的能力 在个体中非侵入性进展）并允许减少 未来临床试验评估治疗的成本和时间 动脉粥样硬化。

The primary objective of this collaborative double-blind placebo- controlled trial is to determine, using a factorial design, whether aspirin (324 mg/day) or lovastatin (20-40 mg/day), over an average treatment period of three years, retards the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Men and women free of clinically evident coronary and cerebrovascualr disease who are 50 years of age or older, with total serum cholesterol levels between approximately the 50th (220 mg/dl) and 90th (260 mg/dl) percentiles and at least one plaque with a thickness between 1.0 and 4.0 mm are eligible for participation. A secondary objective is to determine the safety of long-term therapy with the two active interventions, individually and in combination. Coronary and cerebrovascular events will be monitored and natural history studies conducted. Progression of the atherosclerotic lesions will be determined semi-annually. Mean wall thickness from the far wall of the carotid artery (common, bifurcation and internal) will be the primary outcome measure. Maximum wall thickness/minimum lumen diameter will also be determined as well as a global extent score. The goal of the lipid-lowering treatment is to bring total serum cholesterol below 180 mg/dl. A favorable outcome of the trial will have major public health implications for the prevention/control of atherosclerosis and its complications. The successful employment of B-mode imaging will greatly impact on health care (ability to monitor plaque progression non-invasively in individuals) and permit a reduction in cost and time for future clinical trials evaluating treatment for atherosclerosis.